Pluri Inc. — Form S-1
Filed October 6, 2026 · analyzed by the Registration Agent
S-1
▲ Likely positive
significance 42/100
What the filing says
On August 26, 2026, Pluri Inc. (Nevada biotech, ~$15.2M market cap) entered a securities purchase agreement with Armistice Capital Master Fund Ltd., issuing 1.2M common shares at $1.50 and pre-funded warrants for 1.03M shares at $1.49999, plus 2.23M common purchase warrants at $1.65 exercise price. This S-1 filed October 6, 2026 registers resale of the 2.23M warrant shares by Armistice; Pluri received $2.98M net proceeds from the initial offering and will receive ~$3.68M if all warrants are exercised. The selling shareholder holds 1.29M shares pre-offering (9.99% of class) and may sell all registered shares at market prices.
Why this rating
Financing adds ~$3.7M cash (24% of $15.2M market cap) and 2.2M dilutive shares (~18% current outstanding). Meaningful but not transformational for micro-cap biotech; typical warrant/PIPE structure.
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.